课题基金 / 基金详情

项目摘要

项目成果

Paul A. Goepfert的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): While animal model studies point to the importance of CD8 T cell responses in controlling HIV-1 replication, the specific quality of these cells achieving this control are unknown. Numerous studies have attempted to correlate different parameters of HIV-1 specific CD8 T cells with clinical markers of disease progression; however, inconsistent data has been attained. Also, for the studies that have seen correlations with plasma viral load, it is unclear whether the observed CD8 T cells parameter are just the result of low viral replication rather than a causative factor in controlling this replication. The problem stems from the fact that most assays do not measure the actual function of CD8 T cells in controlling HIV-1 but instead measure potential surrogate markers of this control. Specific Aim 1 of our proposal will analyze the efficiency of HIV-1 CD8 T cell clones in killing and suppressing HIV-1 replication using in vitro viral assays. Every clone will be identified on the basis T cell receptor ¿ gene (TCRB) sequencing. Using polychromatic flow cytometry in specific aim 2, we will sort HIV-1 specific CD8 T cells according to their capacity to express combinations of 4 different functional parameters (IFN-?, IL-2, TNF-a, and CD107). We will then determine which of the specific populations of HIV-1 CD8 T cells is enriched with clones that efficiently control virus in vitro. Our findings will have important implications fro HIV immunopathogenesis and vaccine design by supplying an HIV-1 specific CD8 T cell phenotype that results in efficient HIV-1 control.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The impact of HIV adaptation to CD8 T cells on infection and viral control
Defining the biological relevance of HIV-1 adaptation to CD4 T cell responses
Defining the biological relevance of HIV-1 adaptation to CD4 T cell responses
A Rational Approach for HIV Vaccine T Cell Epitope Selection
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究